

**MSEI LTD**  
**ACKNOWLEDGEMENT**

Acknowledgement No	: 1408201904141033	Date & Time	: 14/08/2019 04:14:10 PM
Symbol	: JPWL		
Entity Name	: Jagdishwar Pharmaceuticals Works Limited		
Compliance Type	: Regulation 33 - Financial Results		
Quarter / Period	: 30/06/2019		
Mode	: E-Filing		

Date: August 14, 2019

To,  
Head- Listing & Compliance  
Metropolitan Stock Exchange of India Ltd. (MSEI),  
4th Floor, Vibgyor Towers, Plot No. C 62,  
G Block, Opp. Trident Hotel,  
Bandra Kurla Complex, Bandra (E),  
Mumbai – 400 098.

**Sub: Outcome of Board Meeting of Jagadishwar Pharmaceutical Works Limited held on August 14, 2019**

**Ref: Regulation 33 (3) of SEBI (Listing Obligation and Disclosures Requirements) Regulations 2015**

Dear Respected Sir / Madam,

With reference to the above captioned subject, outcome of the meeting of the Board of Directors of Jagadishwar Pharmaceutical Works Limited which was held today at 3.30 p.m. and concluded at 4.00 p.m. is as follows:

Approved Unaudited Financial Results of the Company for the quarter ended June 30, 2019 were considered and approved by the Board. Find enclosed herewith a copy of Unaudited Financial Results along with Limited Review Report pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.


You are requested to take note of the same.

Thanking You,

Yours Faithfully,

**For Jagadishwar Pharmaceutical Works Limited**

  
**Swapan Sarkar**  
**Executive Director**  
**DIN : 05149442**



**Encl: As above**

# JAGADISHWAR PHARMACEUTICAL WORKS LIMITED

(CIN : L24232AS1987PLC002803)

Regd Office : 205, HARIBOL ROY MARKET, 2nd FLOOR, A.T.ROAD, GUWAHATI - 781 001

Email : jpw ltd@yahoo.com, Website : jagadishwarpharma.com, Tel : +91 9163513467

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2019**


( In Lacs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.19	31.03.19	30.06.18	31.03.19
		Unaudited	Unaudited	Unaudited	Audited
<b>PART - I</b>					
I	Income From Operations	7.00	75.01	-	634.21
II	Other Income	-	-	-	0.09
III	Total Income from operations (I + II)	7.00	75.01	-	634.30
IV	Expenses				
	(a) Cost of materials consumed	-	-	-	-
	(b) Purchase of stock-in-trade	-	22.00	-	22.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	5.41	52.51	-	611.22
	(d) Employee benefits expense	1.23	2.12	1.48	6.47
	(e) Depreciation and amortisation expense	-	-	-	-
	(f) Finance Cost	-	-	-	-
	(g) Other expenses	3.80	8.35	2.96	14.21
	Total Expenses	10.44	84.98	4.44	653.90
V	Profit (Loss) before exceptional Items and extraordinary items and tax (III-IV)	(3.44)	(9.97)	(4.44)	(19.60)
VI	Exceptional Items	-	-	-	-
VII	Profit from ordinary activities before finance costs and Exceptional Items (V-VI)	-	-	-	-
VIII	Extra Ordinary Items	-	-	-	-
IX	Net Profit/(Loss) before tax (VII-VIII)	(3.44)	(9.97)	(4.44)	(19.60)
X	Tax Expense :				
	(1) Current Tax	-	-	-	0.58
	(2) Deferred Tax	-	-	-	-
	Total Tax Expenses	-	-	-	0.58
XI	<b>Net profit/(Loss) for the period from continuing operations (IX-X)</b>	(3.44)	(9.97)	(4.44)	(20.18)
XII	Profit/(Loss) for the period from discontinuing operations	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-
XIV	Profit/(Loss) for the period from discontinuing operations (after tax)	-	-	-	-
XV	<b>Profit (Loss) for the period (XI + XIV)</b>	(3.44)	(9.97)	(4.44)	(20.18)
XVI	Other Comprehensive Income	-	-	-	-
XVII	Total Comprehensive Income	(3.44)	(9.97)	(4.44)	(20.18)
XVIII	Paid up equity share capital (Face Value of Rs.10/- per Share)	1,522.17	1,522.17	1,522.17	1,522.17
XVIX	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	54.75
XX	Earnings Per Share (EPS)				
	(a) Basic	(0.02)	(0.07)	(0.03)	(0.13)
	(b) Diluted	(0.02)	(0.07)	(0.03)	(0.13)

**Notes :**

- 1 The above results were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 14th August, 2019.
- 2 The above standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34- Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 3 The financial results have been prepared on the basis of same accounting policies which were followed in preparation of financial results for the year ended 31.03.2019
- 4 Figures of the previous Period quarter have been regrouped wherever necessary.

For Jagadishwar Pharmaceuticals



Mr. Swarnajyoti  
Director

(DIN : 05149442)

Date : 14/08/2019

Place: Guwahati

# Shantimay Majumder & Co.

Chartered Accountants

57, Ramesh Mitra Road

Kolkata – 700 025

E-mail : cashantimoy@gmail.com

Ref :

Date :

## LIMITED REVIEW REPORT

To

The Board of Directors,

**Jagadishwar Pharmaceutical Works Limited**

We have reviewed the unaudited financial results of **Jagadishwar Pharmaceutical Works Limited** (“the Company”), for the quarter ended June 30, 2019 together with the notes thereon (the “Statement”). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations, 2015”), Which has been initialed by us for identification purposes. The Statement is the responsibility of the Company’s management and has been approved by the Board of Directors. Further, the management is also responsible to ensure that the accounting policies used in preparation of this Statement are consistent with those used in the preparation of the Company’s opening unaudited Balance Sheet as at April 01, 2016 prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim financial information performed by the independent auditor of the entity” issues by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practiced and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

We draw attention to the following matters:

- a) Note 2 to the Statement which states that the Company has adopted Ind AS for the financial year commencing from April 1, 2019, and accordingly, the Statement has been prepared by the Company’s Management in compliance with Ind AS.
- b) We were neither engaged to review, nor have we review, nor have we reviewed the comparative figures including reconciliation to the Total Comprehensive Income for the quarter ended on June 30, 2018. As set out in note 5 to the Statement, these figures have been furnished by the Management.

For SHANTIMAY MAJUMDER & CO  
Chartered Accountants  
Firm Regd. No. - 317116E  
57, Ramesh Mitra Road, 1st Floor Kol-25

*S. Majumder*

S. Majumder  
Proprietor M No. 053264  
PAN-ADPPM2476E

For Shantimay Majumder & Co.  
Chartered Accountants

Place : Kolkata

Date : 14<sup>th</sup> August, 2019

Saantimoy Majumder  
(Proprietor)  
Membership No : 053264  
Firm Regn. No.: 317116E